8-K: Ventyx Stockholders Approve Eli Lilly Merger

Ventyx Biosciences, Inc. stockholders have approved the Agreement and Plan of Merger with Eli Lilly and Company, paving the way for Ventyx to become a wholly owned subsidiary.

Summary

• Stockholders of Ventyx Biosciences, Inc. approved the Agreement and Plan of Merger with Eli Lilly and Company at a special meeting held virtually on March 3, 2026.
• The merger agreement was approved with 44,176,785 votes For, 1,572,592 Against, and 61,369 Abstain.
• Stockholders also approved, on a non-binding advisory basis, the compensation that will or may become payable to named executive officers in connection with the Merger, with 43,789,693 votes For, 1,838,898 Against, and 182,155 Abstain.
• As of the January 21, 2026 record date, 71,760,778 common shares were issued and outstanding, with 45,810,746 shares represented at the Special Meeting.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive development for Ventyx Biosciences shareholders, as the successful approval of the merger agreement with Eli Lilly provides a clear path to acquisition and likely a premium for their shares.

Positives

• The merger agreement with Eli Lilly and Company received overwhelming approval from stockholders, with over 96% of votes cast in favor, indicating strong support for the transaction.
• The approval facilitates Ventyx Biosciences becoming a wholly owned subsidiary of a major pharmaceutical company, potentially offering enhanced resources and market stability.
• The non-binding advisory vote on executive compensation related to the merger also passed, suggesting alignment between management and stockholders regarding incentives.

Negatives

• Ventyx Biosciences will cease to be an independent publicly traded entity, meaning current stockholders will no longer hold shares in a standalone company.
• A minority of stockholders (1,572,592) voted against the merger agreement, indicating some level of dissent regarding the transaction.

Future Outlook

The approval of the merger agreement by Ventyx Biosciences, Inc. stockholders sets the stage for the company to be acquired by Eli Lilly and Company, with Ventyx becoming a wholly owned subsidiary.

Industry Context

StockSavvy.ai notes that this acquisition by Eli Lilly reflects a continuing trend of larger pharmaceutical companies integrating promising biotechnology firms to expand their pipelines and market reach, particularly in areas where Ventyx Biosciences may have specialized assets or expertise.

Comparison to Industry Standards

• StockSavvy.ai observes that the approval rate for the merger agreement, with over 96% of votes cast in favor (44,176,785 FOR vs. 1,572,592 AGAINST), is robust and generally aligns with successful M&A transactions in the biotechnology sector, such as Pfizer's acquisition of Seagen or AbbVie's acquisition of Allergan, where shareholder approval typically exceeds 90% for agreed-upon deals. This strong mandate suggests shareholder confidence in the strategic rationale and valuation of the deal.

Stakeholder Impact

• Shareholders: Will receive consideration for their shares as Ventyx becomes a wholly owned subsidiary of Eli Lilly.
• Employees: Will become employees of a larger pharmaceutical company, Eli Lilly, potentially impacting roles, benefits, and career paths.
• Management: Executive officers' compensation in connection with the merger was approved on an advisory basis.

Next Steps

• The completion of the merger, where Ventyx Biosciences, Inc. will be merged with RYLS Merger Corporation and survive as a wholly owned subsidiary of Eli Lilly and Company.

Key Dates

Keywords

Ventyx Biosciences, Eli Lilly, Merger, Acquisition, Stockholder Vote, 8-K, Pharmaceuticals, Biotechnology, Corporate Governance